Revolution Medicines, Inc. Common Stock (RVMD) Financials
Key financial figures for Revolution Medicines, Inc. Common Stock (Q2 2026).
Revolution Medicines, Inc. reported revenue of $0.00 for Q2 FY2026. The company posted a net loss of $644.4 million, or -$3.06 per share. Free cash flow for the period was -$389.6 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Revolution Medicines, Inc. are on the SentiSense financials page.
- Revenue
- $0
- Net Income
- -$644M
- EPS
- $-3.06
- Total Assets
- $4.3B
- Operating Cash Flow
- -$387M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $0 | -$644M | -$3.06 | -$390M | |
| Q1 FY2026 | $0 | -$454M | -$2.29 | -$356M | |
| Q4 FY2025 | $0 | -$365M | -$1.90 | -$276M | |
| Q3 FY2025 | $0 | -$305M | -$1.61 | -$211M | |
| Q2 FY2025 | $0 | -$248M | -$1.31 | -$229M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$1.1B | -$5.95 | -$914M | |
| FY2024 | $0 | -$600M | -$3.58 | -$568M | |
| FY2023 | $12M | -$436M | -$3.86 | -4207.12% | -$358M |
Frequently asked questions
What was Revolution Medicines, Inc.'s revenue last quarter?
Revolution Medicines, Inc. reported revenue of $0.00 for Q2 FY2026.
Is Revolution Medicines, Inc. profitable?
Not in its most recent reported period. Revolution Medicines, Inc. reported a net loss of $644.4 million for Q2 FY2026.
How much free cash flow did Revolution Medicines, Inc. generate?
Revolution Medicines, Inc. generated free cash flow of -$389.6 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Revolution Medicines, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.